Valeant Pharmaceuticals (VRX) has projected its adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) to fall $3.6 billion–$3.7 billion. Besides lower revenue, the company will also have to bear $1.9 billion in cash interest in 2017, which includes $100 million in amortized deferred financing costs.
Receive e-mail alerts for new research on VRX:
Interested in VRX?
Don’t miss the next report.
Wall Street analysts have projected that Valeant’s 2017 adjusted non-generally accepted accounting principles (or non-GAAP) net profit margins would be around 15.5%, which represents a year-over-year (or YoY) narrowing of around 430 basis points.
If Valeant manages to surpass these net profit margin projections in 2017, its share price and that of the Global X Top Guru Holdings Index ETF (GURU) may be affected positively. Valeant makes up about 0.19% of GURU’s portfolio.
In 2017, peers Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), and Incyte (INCY) are expected to report adjusted non-GAAP net profit margins close to 27.7%, 34.5%, and $5.3%, respectively.
On February 16, 2017, AstraZeneca and Valeant Pharmaceuticals announced that the FDA has approved Siliq (brodalumab) as a therapy for moderate-to-severe plaque psoriasis in adult patients. On February 27, 2017, Valeant declared that it had refiled a new drug application (or NDA) for latanoprostene bunod ophthalmic solution, a treatment option for open-angle glaucoma (or OAG) patients. On December 8, 2016, Valeant announced positive results of a phase 3 trial evaluating IDP-118 as a therapy for plaque psoriasis patients.
On February 21, 2017, Valeant entered into an agreement with EyeGate Pharma to obtain global manufacturing and marketing rights for its EGP-437 combination therapy and EyeGate II Delivery System, which is used as post-operative care for ocular surgery patients. On February 23, 2017, Valeant entered into a collaboration with Nextcell Medical to further strengthen its Obagi skincare franchise. Valeant is also expanding its Bausch & Lomb lens portfolio in 2017.
By focusing on its late-stage research pipeline, Valeant expects to restore its profitability. In the next article, we’ll explore the impact of headwinds on the performance of Valeant’s business segments in 2016.